1. Pink Sheet
  2. >>Geography
  3. >>Asia

Japan Pricing Reform Process Must Be Participative – Pfizer

 
• By Ian Haydock

Against a background of ongoing discussions in Japan over the reform of the drug pricing and reimbursement system, Pfizer is calling for greater industry participation and recognition of the value of innovation.

Japanese flag

While the main focus of Pfizer Japan Inc.’s annual business update in Tokyo was not surprisingly on the performance, outlook and R&D pipeline of the largest pharma multinational in Japan, the US giant also took the opportunity to present some of its views on ongoing official discussions over drug pricing and reimbursement reforms.

Pointing to the subsidiary’s achievement of 100 new drug approvals in Japan over the past 20 years, and the contribution of these to medical care, country president Ichiro Umeda stressed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Asia

Japan Reimburses 11 New Drugs But Slashes Price Of Others By Up To 20%

 
• By Lisa Takagi

Japan's NHI program continues to give and take as 11 new drugs are granted reimbursement, while the prices of others - including three ophthalmic therapies - are cut by up to 20% under a Market Expansion Repricing scheme.

Korean Pharma Industry Proposes Policies As Election Nears

 
• By Jung Won Shin

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.